Pear Therapeutics (PEAR) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Pear Therapeutics Reports First Quarter 2022 Financial Results
May 16, 2022 4:02 PM EDT108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pears three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code Pear's first 12-month and 24-month real-world health economic data presented at ISPOR



